AI Drug Repurposing Engine PharmAI Launches: Discovering New Indications for Existing Drugs, Cutting R&D from 10 Years to 18 Months

AI Drug Repurposing Engine PharmAI Launches: Discovering New Indications for Existing Drugs, Cutting R&D from 10 Years to 18 Months

On November 5, 2029, Insilico Medicine released the PharmAI drug repurposing engine. The platform systematically discovers new indications for existing drugs through AI analysis of molecular mechanisms of action, gene expression profiles, and clinical data of already-marketed medications. The first PharmAI result — a drug originally for type 2 diabetes found to have significant efficacy against early Alzheimer's disease — has entered Phase III clinical trials.

Drug repurposing's advantage is that safety profiles are already known. The toxicological data and side effect profiles of marketed drugs have been validated through years of clinical use, so even for new indication trials, required safety assessments are dramatically reduced. PharmAI shortens the traditional drug repurposing discovery cycle from 3-5 years to 6-18 months.

"Among all globally marketed drugs, more than 80% likely have undiscovered therapeutic potential," said Insilico Medicine's chief scientific officer. "PharmAI's mission is to systematically mine this hidden therapeutic value."

PharmAI has analyzed the molecular associations of 4,200 marketed drugs and 12,000 diseases, generating over 600 potential new indication candidates. Fifteen pharmaceutical companies have signed usage agreements for PharmAI.